Columbus Circle Investors raised its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 16.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 128,703 shares of the biopharmaceutical company’s stock after purchasing an additional 18,545 shares during the quarter. Columbus Circle Investors owned 0.06% of Incyte Corporation worth $15,025,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Cornerstone Advisors Inc. grew its stake in shares of Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 145 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Incyte Corporation by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 108 shares during the last quarter. Seven Eight Capital LP purchased a new stake in Incyte Corporation during the second quarter valued at about $129,000. IFP Advisors Inc lifted its holdings in Incyte Corporation by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 103 shares during the last quarter. Finally, Sun Life Financial INC increased its position in shares of Incyte Corporation by 9,069.2% during the second quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 1,179 shares during the period. Institutional investors and hedge funds own 89.60% of the company’s stock.
A number of research analysts have commented on the stock. Oppenheimer Holdings, Inc. reiterated a “hold” rating and set a $135.00 price target on shares of Incyte Corporation in a research report on Thursday, August 31st. BMO Capital Markets dropped their price target on Incyte Corporation from $163.00 to $162.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. Barclays PLC reaffirmed an “overweight” rating and issued a $165.00 price target (down previously from $180.00) on shares of Incyte Corporation in a research note on Wednesday, August 2nd. Royal Bank Of Canada initiated coverage on Incyte Corporation in a research report on Thursday, September 14th. They set a “sector perform” rating and a $136.00 price objective for the company. Finally, Raymond James Financial, Inc. raised Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price objective for the company in a research report on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $144.98.
ILLEGAL ACTIVITY NOTICE: “Incyte Corporation (INCY) Shares Bought by Columbus Circle Investors” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/20/incyte-corporation-incy-shares-bought-by-columbus-circle-investors.html.
Incyte Corporation (INCY) traded down $3.38 during trading on Monday, reaching $102.09. 362,093 shares of the company were exchanged, compared to its average volume of 1,932,347. Incyte Corporation has a 1 year low of $98.49 and a 1 year high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.
Incyte Corporation (NASDAQ:INCY) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. During the same quarter last year, the firm posted $0.19 EPS. The business’s quarterly revenue was up 41.6% on a year-over-year basis. equities analysts forecast that Incyte Corporation will post -1.33 EPS for the current year.
Incyte Corporation Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.